Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LNG Energy Announces Signing of Hydrocarbon Productive Participation Contracts (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Ardelyx Inc ARDX

Healthcare Biotechnology
Ardelyx, Inc. is a biopharmaceutical company. The Company focuses on discovery, development, and commercialization of advanced medicines that meet significant unmet medical needs. It has two commercial products IBSRELA (tenapanor) and XPHOZAH. Its product pipeline includes RDX013 Program and RDX020 Program. Tenapanor is a small molecule therapy in development for the treatment of or the control... see more

Recent & Breaking News (NDAQ:ARDX)

Ardelyx Showcases New Data from T3MPO-3 Long-Term Safety Trial of Tenapanor for IBS-C in Presidential Poster at ACG 2018 Annual Meeting

PR Newswire October 8, 2018

Ardelyx to Host Its First Annual Investor Day Focused on Treatment Landscape of Renal Disorders

PR Newswire October 4, 2018

Ardelyx Submits New Drug Application for U.S. Marketing Authorization of Tenapanor for IBS-C to U.S. Food and Drug Administration

PR Newswire September 13, 2018

Ardelyx Announces Science Translational Medicine Publication Detailing Tenapanor's Unique Mechanism of Action Inhibiting Paracellular Phosphate Absorption

PR Newswire August 29, 2018

Consolidated Research: 2018 Summary Expectations for PDF Solutions, MYOS RENS Technology, Aldeyra Therapeutics, The Ensign Group, Everi, and Ardelyx — Fundamental Analysis, Key Performance Indications

GlobeNewswire August 17, 2018

Ardelyx Reports Second Quarter 2018 Financial Results and Recent Highlights

PR Newswire August 7, 2018

Ardelyx Announces Date of Second Quarter 2018 Financial Results and Conference Call

PR Newswire August 1, 2018

Ardelyx to Present at the Jefferies 2018 Global Healthcare Conference

PR Newswire May 29, 2018

Mid-Day Market Update: Dow Falls Over 100 Points; Cara Therapeutics Shares Spike Higher

Benzinga.com  May 23, 2018

Mid-Morning Market Update: Markets Open Lower; Target Earnings Miss Views

Benzinga.com  May 23, 2018

Benzinga's Daily Biotech Pulse: Insmed Presents Data, Pfenex Pulls Back On Offering, Oncolytics Listing

Benzinga.com  May 23, 2018

Mid-Afternoon Market Update: Dow Down 75 Points; Ardelyx Shares Slide

Benzinga.com  May 22, 2018

Mid-Day Market Update: Dycom Industries Falls On Q3 Miss; America's Car-Mart Shares Gain

Benzinga.com  May 22, 2018

8 Stocks Moving In Monday's After-Hours Session

Benzinga.com  May 21, 2018

Ardelyx Reports First Quarter 2018 Financial Results and Recent Business Highlights

PR Newswire May 8, 2018

Ardelyx's Pivotal Phase 3 Study of Tenapanor for IBS-C Hits Primary and All Secondary Endpoints to Support NDA Submission in 2018

PR Newswire October 11, 2017

Ardelyx Focuses Resources on Late-Stage Programs and Reports Second Quarter 2017 Operational Results

PR Newswire August 9, 2017

Investor Network: Ardelyx, Inc. to Host Earnings Call

Accesswire August 9, 2017

Ardelyx Announces Date of Second Quarter Financial Results and Presentation at Wedbush PacGrow Healthcare Conference

PR Newswire August 2, 2017

Biotech Stock Performance Review -- Alder Biopharma, Ardelyx, Bellerophon Therapeutics, and Corbus Pharma

PR Newswire June 26, 2017